Collegium Pharmaceutical (COLL) Net Income Growth (3y) (2017 - 2026)
Collegium Pharmaceutical (COLL) Net Income Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn | 14.04% |
| 3 | Zoetis | 31.45 Bn | 29.77 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -27.09% |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 14.78% |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Collegium Pharmaceutical | 886.99 Mn | 737.67 Mn | 110.29 Mn | -46.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -46.70% |
| Mar 31, 2026 | 41.48% |
| Dec 31, 2025 | 63.32% |
| Sep 30, 2025 | 310.04% |
| Jun 30, 2025 | 62.72% |
| Mar 31, 2025 | 29.76% |
| Dec 31, 2024 | 35.73% |
| Sep 30, 2024 | 5.08% |
| Jun 30, 2024 | -35.43% |
| Mar 31, 2024 | 20.95% |
| Dec 31, 2023 | 66.19% |
| Sep 30, 2023 | 22.28% |
| Jun 30, 2023 | 17.31% |
| Mar 31, 2023 | -343.82% |
| Dec 31, 2022 | -48.44% |
| Sep 30, 2022 | 27.54% |
| Jun 30, 2022 | -3.28% |
| Mar 31, 2022 | -10.43% |
| Dec 31, 2021 | -68.16% |
| Sep 30, 2021 | 27.19% |